squamous cell carcinoma

[Oral Diseases] The authors suggested that in the route to cisplatin chemoresistance, epigenetic modifications could be associated with epithelial-mesenchymal transition activation and cancer stem cell accumulation which originated more aggressive tumors.

[Nature Communications] Researchers showed, by using 16 different stimuli in vitro, that activated dendritic cells in human blood were phenotypically and functionally dichotomous, and pure cultures of type 2 conventional dendritic cells acquired these states upon appropriate stimuli.

[IO Biotech] IO Biotech, a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on its T-win® technology platform, announced that it has dosed the first patient, in metastatic non-small cell lung cancer, in its Phase II IOB-022 / KN-D38 trial.

[IO Biotech] IO Biotech, a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on its T-win® technology platform, announced that it has dosed the first patient, in metastatic non-small cell lung cancer, in its Phase II IOB-022 / KN-D38 trial.

[Ribon Therapeutics] Ribon Therapeutics announced the first patient has been dosed in the Phase Ib/II study of RBN-2397 in combination with the anti-PD-1 checkpoint inhibitor therapy, pembrolizumab, in patients with squamous cell carcinoma of the lung.

[npj Precision Oncology] Investigators highlight new insights into the mutational profile of cutaneous squamous cell carcinoma, summarizes current diagnostic and therapeutic standards, and discusses emerging diagnostic approaches.